Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer.

Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt PM, Silva MD, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJ, Sung JJ, Winawer SJ.

Cancer. 2016 Mar 15;122(6):826-39. doi: 10.1002/cncr.29865. Epub 2016 Feb 1.

2.
3.

Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test.

McNamara D, Leen R, Seng-Lee C, Shearer N, Crotty P, Neary P, Walsh P, Boran G, O'Morain C.

Eur J Gastroenterol Hepatol. 2014 Dec;26(12):1415-21. doi: 10.1097/MEG.0000000000000207.

PMID:
25244415
4.

A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.

Raginel T, Puvinel J, Ferrand O, Bouvier V, Levillain R, Ruiz A, Lantieri O, Launoy G, Guittet L.

Gastroenterology. 2013 May;144(5):918-25. doi: 10.1053/j.gastro.2013.01.042. Epub 2013 Feb 1.

PMID:
23376426
5.

Colon cancer screening and surveillance controversies.

Lieberman D.

Curr Opin Gastroenterol. 2009 Sep;25(5):422-7. doi: 10.1097/MOG.0b013e32832d1e2a. Review.

PMID:
19465849
6.

Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection.

Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM.

Int J Cancer. 2015 Jun 15;136(12):2864-74. doi: 10.1002/ijc.29343. Epub 2014 Dec 3.

7.

Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.

van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E.

Gastroenterology. 2008 Jul;135(1):82-90. doi: 10.1053/j.gastro.2008.03.040. Epub 2008 Mar 25.

PMID:
18482589
8.

[Necessity and feasibility of screening for colorectal cancer in China].

Zhang SZ.

Zhonghua Wei Chang Wai Ke Za Zhi. 2011 Jan;14(1):16-8. Chinese.

PMID:
21271373
9.

Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.

Worthley DL, Smith A, Bampton PA, Cole SR, Young GP.

Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1079-83.

PMID:
16957514
10.

Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.

Chausserie S, Levillain R, Puvinel J, Ferrand O, Ruiz A, Raginel T, Lantieri O, Launoy G, Guittet L.

Int J Cancer. 2015 Apr 15;136(8):1827-34. doi: 10.1002/ijc.29187. Epub 2014 Sep 18.

11.

A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.

Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, Zuckerman GR, Rockey DC.

Am J Gastroenterol. 2000 May;95(5):1331-8.

PMID:
10811348
12.

Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.

Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I.

Dis Colon Rectum. 2011 Jul;54(7):876-86. doi: 10.1007/DCR.0b013e31820fd2bc.

PMID:
21654256
13.

Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.

Hundt S, Haug U, Brenner H.

Ann Intern Med. 2009 Feb 3;150(3):162-9.

PMID:
19189905
14.

Limitations of the faecal occult blood test in screening for colorectal cancer.

Delcò F, Sonnenberg A.

Ital J Gastroenterol Hepatol. 1999 Mar;31(2):119-26.

PMID:
10363196
15.

Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting.

Werner S, Krause F, Rolny V, Strobl M, Morgenstern D, Datz C, Chen H, Brenner H.

Clin Cancer Res. 2016 Apr 1;22(7):1725-33. doi: 10.1158/1078-0432.CCR-15-1268. Epub 2015 Nov 11.

16.

Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.

Chen JG, Cai J, Wu HL, Xu H, Zhang YX, Chen C, Wang Q, Xu J, Yuan XL.

World J Gastroenterol. 2012 Jun 7;18(21):2682-8. doi: 10.3748/wjg.v18.i21.2682.

17.

Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.

Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1158-66. doi: 10.1016/j.cgh.2013.03.013. Epub 2013 Mar 28.

PMID:
23542330
18.

Colorectal cancer screening: scientific review.

Walsh JM, Terdiman JP.

JAMA. 2003 Mar 12;289(10):1288-96. Review.

PMID:
12633191
19.

Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.

Tinmouth J, Lansdorp-Vogelaar I, Allison JE.

Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Review.

PMID:
26041750
20.

Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.

Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG.

J Natl Cancer Inst. 1993 Aug 18;85(16):1311-8.

PMID:
8340943

Supplemental Content

Support Center